2 terminated, 1 completed, 1 recruiting, 1 unknown. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Terminated 2, Completed 1, Recruiting 1, Unknown 1 |
Follow Apixaban 2.5 MG: new trials by email Literature Review of Apixaban 2.5 MG trials Research Report on Apixaban 2.5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial Apixaban 2.5 MG - Venous Thromboembolism, Bleeding | Phase 4 | Recruiting | Clinical Urology and Epidemiology Working Group | 5436 | 2024-06-06 | 2025-05-28 |
| Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Apixaban 2.5 MG, Placebo - Covid19, Thrombosis | Phase 4 | Terminated | Brazilian Clinical Research Institute | 411 | 2021-03-04 | 2022-08-25 |
| Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Apixaban 2.5 MG, Placebo oral tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | Brigham and Women's Hospital | 600 | 2021-03-01 | 2025-11-14 |
| Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access Apixaban 2.5 MG, Active Control - Hemodialysis Access Failure | Phase 4 | Unknown | National Taiwan University Hospital Hsin-Chu Branch | 150 | 2020-03-14 | 2020-07-28 |
| Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG - Venous Thromboembolism | Phase 4 | Terminated | Duke University | 44 | 2018-08-01 | 2019-12-13 |
Venous Thromboembolism (3) · Pulmonary Embolism (2) · Thrombosis (2) · Venous Thrombosis (2) · COVID-19 (1) · Hemorrhage (1)
Brazilian Clinical Research Institute (1) · Brigham and Women's Hospital (1) · Clinical Urology and Epidemiology Working Group (1) · Duke University (1) · National Taiwan University Hospital Hsin-Chu Branch (1)
United States (2) · Brazil (1) · Finland (1) · Taiwan (1)
Kari AO Tikkinen, Professor (1) · Renato D. Lopes, MD, PhD (1) · Thomas Ortel, MD (1)
2023 (1)